Tags

Type your tag names separated by a space and hit enter

Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method.
J Glob Antimicrob Resist. 2017 09; 10:291-294.JG

Abstract

OBJECTIVES

Melioidosis is caused by the bacterium Burkholderia pseudomallei. The most common antibiotics used to treat melioidosis in Australia are meropenem, ceftazidime, trimethoprim/sulfamethoxazole (SXT) and doxycycline. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) do not provide standards for assessing the susceptibility of B. pseudomallei for these agents. The International Standards Organisation (ISO) microbroth dilution method is accepted both by the CLSI and EUCAST as the gold standard of antimicrobial susceptibility testing. Many previous studies of the susceptibility of B. pseudomallei used Etest or disk diffusion and presented the results as aggregate data. Etest and disk diffusion methods have not been standardised for B. pseudomallei and aggregate data cannot be used to determine an epidemiological cut-off value (ECOFF). An ECOFF is vital for the setting of clinical breakpoints.

METHODS

In this study, minimum inhibitory concentrations (MICs) of meropenem, ceftazidime, SXT and doxycycline were assessed by microbroth dilution for a library of 234 well characterised clinical isolates of B. pseudomallei from Northern Queensland, Australia.

RESULTS

The resultant histograms and aggregate data represent the first MIC profile of a large library of B. pseudomallei that has been successfully produced using microbroth dilution.

CONCLUSIONS

The MIC profiles can be used to contribute towards a determination of an ECOFF for this species for these agents, which will aid in the setting and refining of clinical breakpoints for the most important antimicrobials used to treat melioidosis.

Authors+Show Affiliations

The Townsville Hospital, Townsville, QLD 4814, Australia; Microbiology, Pathology Queensland, Townsville, QLD 4814, Australia. Electronic address: samuel.maloney@health.qld.gov.au.Microbiology, Pathology Queensland, Townsville, QLD 4814, Australia.The Townsville Hospital, Townsville, QLD 4814, Australia; Microbiology, Pathology Queensland, Townsville, QLD 4814, Australia.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28729203

Citation

Maloney, Samuel, et al. "Epidemiological Cut-off Value of Clinical Isolates of Burkholderia Pseudomallei From Northern Queensland to Meropenem, Ceftazidime, Trimethoprim/sulfamethoxazole and Doxycycline By the Microbroth Dilution Method." Journal of Global Antimicrobial Resistance, vol. 10, 2017, pp. 291-294.
Maloney S, Engler C, Norton R. Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method. J Glob Antimicrob Resist. 2017;10:291-294.
Maloney, S., Engler, C., & Norton, R. (2017). Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method. Journal of Global Antimicrobial Resistance, 10, 291-294. https://doi.org/10.1016/j.jgar.2017.04.012
Maloney S, Engler C, Norton R. Epidemiological Cut-off Value of Clinical Isolates of Burkholderia Pseudomallei From Northern Queensland to Meropenem, Ceftazidime, Trimethoprim/sulfamethoxazole and Doxycycline By the Microbroth Dilution Method. J Glob Antimicrob Resist. 2017;10:291-294. PubMed PMID: 28729203.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method. AU - Maloney,Samuel, AU - Engler,Cathy, AU - Norton,Robert, Y1 - 2017/07/18/ PY - 2017/01/16/received PY - 2017/04/11/revised PY - 2017/04/14/accepted PY - 2017/7/22/pubmed PY - 2019/6/14/medline PY - 2017/7/22/entrez KW - Burkholderia pseudomallei KW - Clinical breakpoints KW - Epidemiological cut-off (ECOFF) KW - Melioidosis KW - Minimum inhibitory concentration SP - 291 EP - 294 JF - Journal of global antimicrobial resistance JO - J Glob Antimicrob Resist VL - 10 N2 - OBJECTIVES: Melioidosis is caused by the bacterium Burkholderia pseudomallei. The most common antibiotics used to treat melioidosis in Australia are meropenem, ceftazidime, trimethoprim/sulfamethoxazole (SXT) and doxycycline. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) do not provide standards for assessing the susceptibility of B. pseudomallei for these agents. The International Standards Organisation (ISO) microbroth dilution method is accepted both by the CLSI and EUCAST as the gold standard of antimicrobial susceptibility testing. Many previous studies of the susceptibility of B. pseudomallei used Etest or disk diffusion and presented the results as aggregate data. Etest and disk diffusion methods have not been standardised for B. pseudomallei and aggregate data cannot be used to determine an epidemiological cut-off value (ECOFF). An ECOFF is vital for the setting of clinical breakpoints. METHODS: In this study, minimum inhibitory concentrations (MICs) of meropenem, ceftazidime, SXT and doxycycline were assessed by microbroth dilution for a library of 234 well characterised clinical isolates of B. pseudomallei from Northern Queensland, Australia. RESULTS: The resultant histograms and aggregate data represent the first MIC profile of a large library of B. pseudomallei that has been successfully produced using microbroth dilution. CONCLUSIONS: The MIC profiles can be used to contribute towards a determination of an ECOFF for this species for these agents, which will aid in the setting and refining of clinical breakpoints for the most important antimicrobials used to treat melioidosis. SN - 2213-7173 UR - https://www.unboundmedicine.com/medline/citation/28729203/Epidemiological_cut_off_value_of_clinical_isolates_of_Burkholderia_pseudomallei_from_Northern_Queensland_to_meropenem_ceftazidime_trimethoprim/sulfamethoxazole_and_doxycycline_by_the_microbroth_dilution_method_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-7165(17)30093-0 DB - PRIME DP - Unbound Medicine ER -